Clinical Evaluation of COPD Butler in Patient Home Management

Effect of the Integrated Network Management of Stable Hypercapnic COPD Patients With Domiciliary Noninvasive Ventilation Treatment

Chronic Obstructive Pulmonary Disease (COPD) is a worldwide common disease with high morbidity and mortality and leads to heavy social and economic burden. Health management of stable COPD patients has been suggested to be essential for delaying diseases progress, reducing acute exacerbation events and improving patient quality of life. Non-invasive ventilation (NIV) is a widely used treatment in COPD patients. There were studies shown that NIV could improve ventilation, blood gases etc., and several clinical trials have shown improvements in survival, exercise capacity, quality of life and so on. Compliance to NIV and optimal parameter setting are important factors that will affect the effect of the use of NIV, thus NIV usage monitoring might also be a crucial element in the health management of COPD patients. Many studies have been designed to study the effect of tele-monitoring program on the management of COPD patients. However, almost none of these studies were designed for specific population, and little is known about the effect of such program on the management of patients with NIV treatment.

Study Overview

• Status: Recruiting
• Conditions: COPD; Hypercapnic Respiratory Failure
• Intervention / Treatment: Device: NIV with the integrated tele-monitoring management program

Detailed Description

The COPD home management program consists of 3 Philips devices (NIV BiPAP ST, Oximeter and Blood Pressure Meter), a patient mobile APP which is developed for self-management at home and a professional physician web portal which is designed for NIV usage and other vital sign data monitoring. The program is intended to manage the post-discharge COPD patient by enhancing COPD patient condition monitoring and adherence to the home therapy, e.g. NIV in this study. Besides obtaining clinical proof points of the efficacy of such program on patients with NIV treatment, it will provide potential evidence of the usability as well as the collect the insights for future product improvement.

• Study Type: Interventional
• Enrollment (Anticipated): 166
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Luqian Zhou, PhD; Phone Number: +8615622236759; Email: zhlx09@163.com

Study Locations

• China
  • Guangdong
    • Guangzhou, Guangdong, China, 510120
      • Recruiting
      • The First Affiliated Hospital of Guangzhou Medical University.
      • Contact: Lili Guan, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Age 40-80, males and females
2. Stage III and IV COPD
3. Daytime hypercapnia (PaCO2 ≥ 50 mmHg) at rest without ventilatory support
4. Possess home oxygen concentrator
5. Participants/Caregivers have access to and capable of using smartphone and internet
6. Willing to participate in the study
7. Able to provide informed consent

Exclusion Criteria:

1. Subjects with NIV as routine therapy prior to the study
2. Subjects with abnormalities of the lung or thorax other than COPD
3. Subjects with obstructive sleep apnea, COPD with obstructive sleep apnea overlap syndrome, severe heart failure, severe arrhythmias, unstable angina, and malignant comorbidities
4. Subjects with significantly impaired cognitive function and are unable to fulfill the study requirement (unable to provide informed consent)
5. Subjects who participated in another trial within 30 days prior to the planned start of study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Intervention group; Intervention group subjects will use NIV with the integrated tele-monitoring management program as home therapy and accomplish the following tasks via mobile COPD Butler APP: 1) upload daily NIV usage data， blood pressure, oxygen saturation, and heart rate measurement; 2) daily medication taken recording; 3) regular self-reported health questionnaire and symptom recording; 4) read health education materials. Information collected from the intervention group by the APP will be monitored by physician team from the leading hospital through physician web portal. The physician team will provide regular health report, and once an alert is generated due to the abnormality in NIV usage or vital sign data etc., physicians will take action accordingly.	Device: NIV with the integrated tele-monitoring management program; Noninvasive positive pressure ventilation with the integrated tele-monitoring management will provide regular health report, and once an alert is generated due to the abnormality in NIV usage or vital sign data etc., physicians will take action accordingly.
No Intervention: Control group; Control group subjects will only use NIV according to their treatment plan at home. NIV usage data will be read from the NIV secure digital memory card for the control group.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adherence to NIV treatment	The primary objective is to test the effect of COPD tele-monitoring program on patient's adherence to NIV treatment.	12th month

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Acute exacerbation of COPD re-admission rate	Acute exacerbation which was characterized as an acute worsening of more than one respiratory symptom (new onset of or increase in sputum volume or purulence, wheezing, cough, dyspnoea, or fever) lasting for at least 2 consecutive days and result in any changes in their conventional therapy.	Baseline, 1st, 3rd, 6th and 12th month
Severe Respiratory Insufficiency (SRI) Questionnaire	The SRI Questionnaire has good psychometric properties shown to be valid for chronic hypercapnic COPD patients receiving NIV. It includes 49 items on seven subscales.	Baseline, 3rd, 6th and 12th month
COPD assessment test	The COPD Assessment Test is a questionnaire for people with COPD. It is designed to measure the impact of COPD on a person's life, and how this changes over time.	Baseline, 1st, 3rd, 6th and 12th month
Partial pressure of arterial blood carbon dioxide (PaCO2)	Daytime arterial blood gas samples were taken with patients resting in a sitting position and breathing room air without having used NIV for at least 1 hour.	Baseline, 1st, 3rd, 6th and 12th month
6-minute walk test	The 6-minute walk test plays a key role in evaluating functional exercise capacity, assessing prognosis and evaluating response to treatment across a wide range of respiratory diseases.	Baseline, 3rd, 6th and 12th month
Forced vital capacity	Forced vital capacity is measured in a test known as spirometry, a type of pulmonary function test, which is used to help determine both the presence and severity of lung diseases.	Baseline, 3rd, 6th and 12th month
Forced expiratory volume in 1 second	Forced expiratory volume in 1 second is a marker used to measure lung function and can help you monitor your lung diseases over time.	Baseline, 3rd, 6th and 12th month
Baseline Dyspnea Index/Transition Dyspnea Index	Baseline Dyspnea Index/Transition Dyspnea Index provides a multidimensional measurement of dyspnea based on 3 components that evoke dyspnea in activities of daily living, in symptomatic individuals.	Baseline, 3rd, 6th and 12th month
COPD self-efficacy scale	Identifying situations in which individuals with COPD experience low self-efficacy is important.	Baseline, 6th and 12th month

Collaborators and Investigators

• Sponsor: The First Affiliated Hospital of Guangzhou Medical University
• Collaborators: Guangdong Provincial Hospital of Traditional Chinese Medicine; Guangzhou First People's Hospital; Shenzhen People's Hospital; Dongguan People's Hospital; Huizhou Municipal Central Hospital; Guangdong Second Provincial General Hospital; Clifford Hospital, Guangzhou, China; Shenzhen Sixth People's Hospital; Subei People's Hospital of Jiangsu Province
• Investigators: Study Director: Rongchang Chen, MD, Guangzhou Institute of Respiratory Health

Study record dates

Study Major Dates

• Study Start (Actual): April 1, 2018
• Primary Completion (Anticipated): December 31, 2022
• Study Completion (Anticipated): December 31, 2022

Study Registration Dates

• First Submitted: March 13, 2018
• First Submitted That Met QC Criteria: March 19, 2018
• First Posted (Actual): March 20, 2018

Study Record Updates

• Last Update Posted (Actual): March 2, 2021
• Last Update Submitted That Met QC Criteria: February 26, 2021
• Last Verified: February 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Respiration Disorders; Signs and Symptoms, Respiratory; Respiratory Insufficiency; Hypercapnia
• Other Study ID Numbers: GIRH-201801

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No